Your browser doesn't support javascript.
loading
Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
Wick, A; Sander, A; Koch, M; Bendszus, M; Combs, S; Haut, T; Dormann, A; Walter, S; Pertz, M; Merkle-Lock, J; Selkrig, N; Limprecht, R; Baumann, L; Kieser, M; Sahm, F; Schlegel, U; Winkler, F; Platten, M; Wick, W; Kessler, T.
Afiliação
  • Wick A; Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  • Sander A; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
  • Koch M; Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  • Bendszus M; Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany.
  • Combs S; Department of Radiation Oncology at the Klinikum Rechts der Isar, Technical University Munich, Munich, Germany.
  • Haut T; Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  • Dormann A; Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  • Walter S; Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  • Pertz M; Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.
  • Merkle-Lock J; Coordination Centre for Clinical Trials (KKS), Medical Faculty & University Hospital Heidelberg, Heidelberg, Germany.
  • Selkrig N; Coordination Centre for Clinical Trials (KKS), Medical Faculty & University Hospital Heidelberg, Heidelberg, Germany.
  • Limprecht R; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
  • Baumann L; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
  • Kieser M; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
  • Sahm F; Department of Neuropathology, University Hospital Heidelberg, DKTK and CCU Neuropathology, DKFZ, Heidelberg, Germany.
  • Schlegel U; Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.
  • Winkler F; Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  • Platten M; German Cancer Consortium (DKTK), Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Wick W; DKTK, Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, DKFZ, Heidelberg, Germany.
  • Kessler T; Department of Neurology, Medical faculty, MCTN, University of Heidelberg, Mannheim, Germany.
BMC Cancer ; 22(1): 645, 2022 Jun 13.
Article em En | MEDLINE | ID: mdl-35692047
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligodendroglioma / Neoplasias Encefálicas Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adult / Humans Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligodendroglioma / Neoplasias Encefálicas Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adult / Humans Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha